

9th International Conference on
Predictive, Preventive & Personalized Medicine & Molecular Diagnostics
&
3rd International Conference on **Integrative Medicine & Alternative treatments**
October 26-27, 2018 | Boston, USA



Ron Ribitzky

R&D Ribitzky, USA

Precision medicine: We the consumers

The Total Addressable Market (TAM) for Precision Medicine is on a trajectory of 10%+ CAGR to surpass \$100B around 2025 as patient demand is on the rise, the cost of human genome sequencing continues to go down, AI happens deep inside the chip, blockchain is heading everywhere and medical devices are just about to switch channel to IoT chat. Yet, it still takes 10+ years for basic science discovery to make a difference in the life of the first consumer it was intended for. In this session, we will re-examine the everelusive Precision Medicine Paradox, white space R&D, healthcare in disruption and we the consumers.

Biography

Ron Ribitzky, founder & CEO of R&D Ribitzky, he is a physician executive with extensive experience in the Convergent Healthcare IT, Life-Sciences Informatics and Precision Medicine. He worked for and with global leading brands and world-class organizations, R&D and academia in the US and 23 developed and emerging economy countries; in addition to ten years in clinical practice. Previously, he co-founded SPH Analytics and served as a Senior Healthcare Strategist at Intel, VP Advanced Research at Eclipsys, CIO at UMass Medical Center, among others. He published, presented and led workshops around the world on technology innovation and practice in industry events, public sector and academia; and held academic appointments at Harvard, UMass, Emory, Weizmann Institute of Science (Israel), Kigali Institute of Science & Technology and Kigali Health Institute (Rwanda). He is a member of HIMSS Blockchain Work Group and Strategic Advisor to Blockchain start-ups ARNA Genomics, BitMed and Cryptfunder, among others.

Ron@RDRibitzky.com

Notes: